Photo taken from ESMO/LinkedIn
Sep 15, 2024, 10:47
No role for pre-operative CRT in the treatment of operable Gastric cancer – ESMO
ESMO shared on LinkedIn:
“Final results presented at ESMO24 from the phase III TOPGEAR trial show that the addition of pre-operative chemoradiotherapy (CRT) to peri-operative chemotherapy improved pathological outcomes but not long-term OS in patients with resectable Gastric Cancer and Gastro-oesophageal Cancer.
For Elizabeth Smyth, the findings confirm that there is no role for pre-operative CRT in the treatment of operable Gastric cancer. CRT appeared to effectively target the local tumour, but did not address distant metastases, which remain the primary cause of mortality.
Read the full news on the ESMO Daily Reporter.”
Source: ESMO/LinkedIn
More posts featuring ESMO24 on oncodaily.com
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18
Dec 21, 2024, 11:12
Dec 21, 2024, 11:06
Dec 21, 2024, 10:38